<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed results of 40 infants less than 2 years of age who received bone marrow transplants (BMT) between May 1974 and January 1995 for treatment of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; N = 34) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; N = 6) to determine outcome and survival performance </plain></SENT>
<SENT sid="1" pm="."><plain>Among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, 13 were in first remission, 9 were in untreated first relapse or second remission, and 12 were in refractory relapse </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were conditioned with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in combination with either total body irradiation (TBI; N = 29) or <z:chebi fb="0" ids="28901">busulfan</z:chebi> (N = 11) </plain></SENT>
<SENT sid="3" pm="."><plain>Source of stem cells included 6 autologous donors, 15 HLA genotypically identical siblings, 14 haploidentical family members, and 5 unrelated donors </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis was <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) for 17, MTX plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSP) for 14, or CSP plus <z:chebi fb="0" ids="8382">prednisone</z:chebi> for 3 </plain></SENT>
<SENT sid="5" pm="."><plain>Incidence of severe (grade 3-4) regimen-related toxicity was 10% and transplant-related mortality was 10% </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD (grades II-III) occurred in 39% of allogeneic patients, and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD developed in 40% </plain></SENT>
<SENT sid="7" pm="."><plain>Relapse, the most significant problem for patients in this study, occurred in 1 MDS patient and 23 AML patients and was the cause of <z:hpo ids='HP_0011420'>death</z:hpo> for 19 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The 2-year probabilities of relapse are 46%, 67%, and 92%, respectively, for patients transplanted in first remission, untreated first relapse or second remission, and relapse </plain></SENT>
<SENT sid="9" pm="."><plain>One <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 8 AML patients received second marrow transplants for treatment of relapse, and 5 of these survive disease-free for more than 1.5 years </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 6 MDS patients and 11 of 34 AML patients survive more than 1.5 years later </plain></SENT>
<SENT sid="11" pm="."><plain>The 5-year probabilities of survival and disease-free survival are 54% and 38% for patients transplanted in first remission and 33% and 22% for untreated first relapse or second remission </plain></SENT>
<SENT sid="12" pm="."><plain>None of the patients transplanted with refractory relapse survive disease-free </plain></SENT>
<SENT sid="13" pm="."><plain>Outcome was significantly associated with phase of disease at transplantation and pretransplant diagnosis of extramedullary disease </plain></SENT>
<SENT sid="14" pm="."><plain>Long-term sequelae included <z:hpo ids='HP_0001510'>growth failure</z:hpo> and hormonal deficiencies </plain></SENT>
<SENT sid="15" pm="."><plain>Survival performance was a median of 100% (80% to 100%) and neurologic development for <z:hpo ids='HP_0000001'>all</z:hpo> survivors was appropriate for age </plain></SENT>
<SENT sid="16" pm="."><plain>This study indicates that infants with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> have similar outcome after BMT compared with older children and that BMT should be performed in first remission whenever possible </plain></SENT>
<SENT sid="17" pm="."><plain>In addition, allogeneic BMT provides effective therapy for the majority of infants with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>